Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8552W HIGH $14.50
Volume
1.79 M
Value Traded
39.29 K
Short % Float
3.69%
+0.24%Week
-18.97%1 Month
-67.7%3 Month
-80.44%6 Month
-93.94%5 Year
-93.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.47 M
EPS (TTM)
-3.24
P/E Ratio
-
Ent. Value
1.08 M
Total Shares
3.57 M
Float Shares
3.22 M
Insiders
9.66%
Institutions
10.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CVKD Catalyst Timeline
Dated clinical, regulatory and corporate events for Cadrenal Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cadrenal Therapeutics, Inc.
116Total events
5Upcoming
28Tier-1 (high impact)
2023 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Rare Pediatric DiseasetecarfarinDesignation
Submitted request to FDA for Rare Pediatric Disease Designation for tecarfarin
Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Diseasesource ↗
●R&D DayPresentation
Cadrenal management one-on-one meetings at Lytham Partners Fall 2026 Investor Conference
▲FDA Feedback ReceivedCAD-1005FDA Meeting
Positive feedback from FDA Type D meeting announced
heparin-induced thrombocytopeniasource ↗
▼Equity OfferingCorporate
Private placement generating approximately $3.0 million in gross proceeds
▲FDA Feedback ReceivedCAD-1005FDA Meeting
Achieved regulatory guidance on Phase 3 path for CAD-1005
heparin-induced thrombocytopenia (HIT)source ↗
▲Type D MeetingCAD-1005FDA Meeting
FDA Type D Meeting held on July 28, 2026
heparin-induced thrombocytopeniasource ↗
▲FDA Feedback ReceivedCAD-1005FDA Meeting
FDA agreed on optimized definition of worsening HIT for primary endpoint
heparin-induced thrombocytopeniasource ↗
◆Partnership / LicenseCorporate
Initiated partnering process for CAD-1005, frunexian, and tecarfarin
▲Oral PresentationCAD-1005Presentation
Late-breaking oral presentation of Phase 2 data at ISTH 2026 Congress
Heparin-Induced Thrombocytopenia (HIT)source ↗
▲Topline ReadoutCAD-1005Clinical Data
Phase 2 topline data: >25% reduction in thrombotic events
Heparin-Induced Thrombocytopenia (HIT)source ↗
◆Rare Pediatric DiseasetecarfarinDesignation
Submitted RPDD request to FDA for tecarfarin for Kawasaki Disease
prevention of life-threatening blood clots inside coronary artery aneurysms in children with Kawasaki Diseasesource ↗
▲Oral PresentationCAD-1005Presentation
Late-breaking Phase 2 data on CAD-1005 presented at ISTH 2026 Congress
heparin-induced thrombocytopenia (HIT)source ↗
◆Oral PresentationPresentation
Presentation at 2026 BIO International Convention in San Diego
◆Partnership / LicenseCAD-1005Corporate
Strategic collaboration and licensing meetings at BIO 2026
◆Oral PresentationPresentation
Cadrenal Therapeutics webcast presentation at Lytham Partners Spring 2026 Investor Conference
▲End Of Phase 2 MeetingCAD-1005FDA Meeting
End-of-Phase 2 meeting with FDA; official minutes received providing guidance on pivotal Phase 3 trial design
heparin-induced thrombocytopenia (HIT)source ↗
▲End Of Phase 2 MeetingCAD-1005FDA Meeting
End-of-Phase 2 meeting with FDA completed
heparin-induced thrombocytopenia (HIT)source ↗
◆End Of Phase 2 MeetingCAD-1005FDA Meeting
End-of-Phase 2 meeting with FDA completed
heparin-induced thrombocytopenia (HIT)source ↗
▲Preclinical PoCCAD-1005Preclinical
Preclinical findings supporting 12-LOX inhibition in obesity and type 2 diabetes highlighted
obesity and type 2 diabetessource ↗
▲Topline ReadoutCAD-1005Clinical Data
Encouraging Phase 2 data for CAD-1005 in HIT demonstrated reduction in thrombotic events
heparin-induced thrombocytopenia (HIT)source ↗
◆End Of Phase 2 MeetingCAD-1005FDA Meeting
End-of-Phase 2 meeting with FDA scheduled for March 2026
heparin-induced thrombocytopenia (HIT)source ↗
▲Topline ReadoutCAD-1005Clinical Data
Phase 2 results show >25% absolute reduction in thrombotic events with CAD-1005 vs placebo
heparin-induced thrombocytopenia (HIT)source ↗
▲Program DiscontinuationCorporate
Competitor's Phase 3 trial in CSA-AKI discontinued for lack of efficacy
Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)source ↗
▲Partnership / LicensetecarfarinCorporate
Cadrenal acquired Factor XIa inhibitor portfolio from eXIthera
anticoagulation for patients with kidney dysfunction or LVADssource ↗
▲Partnership / LicenseVLX-1005Corporate
Cadrenal acquired VLX-1005, a first-in-class 12-LOX inhibitor
heparin-induced thrombocytopenia (HIT)source ↗
▲Partnership / LicenseVLX-1005Corporate
Cadrenal Therapeutics acquires VLX-1005 from Veralox Therapeutics
Heparin-Induced Thrombocytopenia (HIT)source ↗
●Trial DiscontinuedCAD-1005Trial
Phase 2 trial stopped in December 2025 after program ownership transfer
heparin-induced thrombocytopenia (HIT)source ↗
▼Primary Endpoint MissedCAD-1005Clinical Data
Primary endpoint of platelet count recovery not met
heparin-induced thrombocytopenia (HIT)source ↗
▲Secondary Endpoint DataCAD-1005Clinical Data
Secondary endpoint of thrombotic events showed encouraging reduction
heparin-induced thrombocytopenia (HIT)source ↗
◆AcquisitionCorporate
Cadrenal acquires eXIthera's portfolio of Factor XIa inhibitors including frunexian and EP-7327
◆Trial InitiationtecarfarinTrial
Plans to initiate clinical trial for tecarfarin in ESKD patients transitioning to dialysis
End-Stage Kidney Disease (ESKD) transitioning to dialysissource ↗
◆Trial InitiationtecarfarinTrial
Clinical trial initiation plans announced for tecarfarin in ESKD patients transitioning to dialysis
End-Stage Kidney Disease (ESKD) transitioning to dialysissource ↗
▲Manufacturing MilestonetecarfarinCMC / Inspection
Completed technical transfer of tecarfarin to U.S. site of global CDMO and manufactured drug product
▲Partnership / LicensetecarfarinCorporate
Collaboration Agreement with Abbott to support TECH-LVAD trial
patients with HeartMate 3 LVADsource ↗
▲Partnership / LicensetecarfarinCorporate
Collaboration Agreement with Abbott for TECH-LVAD trial
LVAD patientssource ↗
▲Manufacturing MilestonetecarfarinCMC / Inspection
Technical transfer and manufacturing of tecarfarin API to US CDMO completed
Past FDA Catalysts and PDUFA Decisions
How CVKD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-11 | CAD-1005 | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F19 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 96%
Micro Cap(rank 632 of 658)
Percentile Rank
Cadrenal Therapeutics, Inc. has significant pipeline risk (19/100), with $53M risk-adjusted pipeline value, led by VLX-1005 in Safety and Tolerability in Healthy Volunteers (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VLX-1005 Small moleculeCompletedNCT05325346 | Heparin-induced Thrombocytopenia | Phase 1 | COMPLETED | 12 | Apr 14, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CVKD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CAD-1005 Fast TrackOrphan | Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) | Phase 2 | 2026-08-03 | greater than 25%Read More | Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 DiscontinuationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pham Quang XDirector, Officer (Chairman and CEO), 10% Owner | Sell | -7,400 98,589 held | $3.03 | 06/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CVKD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CVKD for Q2 2026. | ||||
CVKD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CVKD ranks across every disease it competes in
Competitive Position is a premium feature
See how CVKD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCVKD News
CVKD▼ -5%today
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Cadrenal Therapeutics has initiated a formal strategic process to explore opportunities for maximizing the value of its assets, including CAD-1005, following alignment with the FDA on its Phase 3 development pathway. The company has engaged Tungsten Advisors as its exclusive financial advisor and has received significant interest from potential partners. However, there is no guarantee that this process will result in any transactions.
Read more →CVKDCadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026. CEO Quang X. Pham will present via webcast and hold one-on-one meetings with investors. The company focuses on therapies for critical care cardiology and has a promising pipeline, including CAD-1005 and tecarfarin, both of which have received FDA designations.
Read more →CVKDCadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Cadrenal Therapeutics, Inc. will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14-16, 2026. CEO Quang X. Pham will present on the company's Cardiac Acute Critical Care Franchise and recent Phase 2 clinical data for CAD-1005. A pre-recorded presentation will be available starting September 11, 2026.
Read more →CVKD▲ +13.6%on this newsshared move
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics received positive feedback from the FDA during a Type D meeting regarding the Phase 3 registration study of CAD-1005 for treating heparin-induced thrombocytopenia (HIT). The FDA agreed on the primary endpoint and statistical analysis plan, which aims to evaluate the drug's effectiveness in reducing thrombotic events. CAD-1005 is positioned to target an unmet need in a significant patient population, with a projected revenue opportunity of $2 billion.
Read more →CVKDCadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Cadrenal Therapeutics reported its Q2 2026 financial results and updates on its Cardiac Acute Critical Care Franchise. The company achieved regulatory guidance for CAD-1005's Phase 3 path and presented promising Phase 2 data at an international congress. Cadrenal is pursuing a structured partnering process to enhance its portfolio and address unmet needs in critical care cardiology.
Read more →CVKDCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Cadrenal Therapeutics has consolidated its strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This move follows the discontinuation of a competitor's Phase 3 trial, highlighting the urgent need for novel treatments in this area. CAD-1005 has shown promising clinical data, positioning it as a first-in-class therapy in a lucrative market.
Read more →CVKDCadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Cadrenal Therapeutics has initiated a partnering process for its cardiac acute critical care assets, including CAD-1005, frunexian, and tecarfarin. The company aims to secure strategic partnerships for these late-stage therapies following positive Phase 2 data presented at the ISTH 2026 Congress. This strategic alignment is designed to maximize asset value and address unmet needs in critical care cardiology.
Read more →CVKD▼ -16.3%on this news
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Cadrenal Therapeutics presented late-breaking Phase 2 data for CAD-1005 at the ISTH 2026 Congress, showing over a 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). This trial is notable as the first randomized, blinded, placebo-controlled study in this area. The results support the advancement of CAD-1005 towards Phase 3 trials, addressing a significant medical need.
Read more →CVKD▼ -5.1%on this news
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Cadrenal Therapeutics has announced a private placement of up to $8.8 million, with $3 million upfront and potential additional proceeds from warrants. The funds are expected to extend the company's cash runway into 2027, allowing for the advancement of therapies for Kawasaki Disease and other conditions. The offering is set to close on July 1, 2026, pending customary conditions.
Read more →CVKDCadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Cadrenal Therapeutics announced that its Phase 2 study of CAD-1005 has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This trial is the first randomized, blinded, placebo-controlled study for Heparin-Induced Thrombocytopenia (HIT), a serious blood-clotting disorder. The presentation will highlight the clinical potential of CAD-1005, a novel 12-lipoxygenase inhibitor, which could transform treatment for HIT patients.
Read more →CVKD▲ +12.9%on this newsshared move
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Cadrenal Therapeutics is preparing to file for a Rare Pediatric Disease Designation for tecarfarin, aimed at treating Kawasaki disease in children. This designation could lead to a Priority Review Voucher, enhancing the drug's market potential. The company will showcase its initiatives at the upcoming BIO International Convention, highlighting its Phase 3-ready pipeline.
Read more →CVKD▼ -10%on this newsshared move
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Cadrenal Therapeutics announced plans to initiate a Phase 2a clinical trial for CAD-1005, targeting Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This indication expands the drug's potential market, estimated at $1 billion annually, as there are currently no FDA-approved therapies for CSA-AKI. The trial aims to generate safety and efficacy data while leveraging existing research on CAD-1005's use in heparin-induced thrombocytopenia (HIT). Discussions about this strategy will take place at the upcoming BIO 2026 conference.
Read more →CVKDCadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Cadrenal Therapeutics is set to showcase its Phase 3-ready CAD-1005 and 12-LOX platform at the BIO International Convention 2026. CAD-1005 targets Heparin-Induced Thrombocytopenia (HIT) and has received FDA designations for its potential to address unmet medical needs. The company aims to explore broader applications for its 12-LOX inhibitor platform, which may impact various inflammatory diseases. Tecarfarin, another late-stage product, is designed for patients with complex anticoagulation needs.
Read more →CVKDCadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will host a webcast presentation and one-on-one meetings with investors. Cadrenal is focused on developing therapies for immune and thrombotic conditions, including its lead program CAD-1005, which targets heparin-induced thrombocytopenia.
Read more →CVKDCadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Cadrenal Therapeutics reported its Q1 2026 financial results and provided an update on its CAD-1005 program following an End-of-Phase 2 meeting with the FDA. The company plans to advance to a pivotal Phase 3 trial for CAD-1005, aimed at treating heparin-induced thrombocytopenia (HIT). The trial will evaluate CAD-1005's efficacy in approximately 120 patients and is intended to support a New Drug Application by 2029. Positive Phase 2 data indicated a significant reduction in thrombotic events, reinforcing the drug's potential.
Read more →CVKD▲ +19.3%on this news
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Cadrenal Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, receiving guidance for a pivotal Phase 3 trial of CAD-1005 in treating heparin-induced thrombocytopenia (HIT). The Phase 2 results indicated a significant reduction in thrombotic events when CAD-1005 was added to standard therapy. The upcoming Phase 3 study aims to evaluate CAD-1005's efficacy in a randomized, placebo-controlled setting.
Read more →CVKD▲ +20.5%on this news
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Cadrenal Therapeutics reported its fourth quarter 2025 financial results and provided an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company completed its End-of-Phase 2 meeting with the FDA, clarifying the path for a Phase 3 trial. Encouraging Phase 2 results showed a significant reduction in thrombotic events, reinforcing CAD-1005's potential as a treatment option.
Read more →About Cadrenal Therapeutics, Inc.
Headquarters822 A1A NORTH, PONTE VEDRA, FL, 32082
BIOPHARMAWATCH ELITE PLUS
Trade the next CVKD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime